Impact of BAFF Gene Polymorphisms on the Risk of Ulcerative Colitis and the Efficacy of Vedolizumab.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07564895

Enrollment

841

Registered

2026-05-04

Start date

2018-03-01

Completion date

2025-06-30

Last updated

2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis (UC)

Keywords

ulcerative colitis

Brief summary

Relationships of B-cell Activating Factor Gene Polymorphisms With ulcerative colitis.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* diagnosed UC based on comprehensive clinical, colonoscopy, histopathological, laboratory, and radiographic examination results

Exclusion criteria

* rheumatoid arthritis, systemic lupus erythematosus, intestinal tuberculosis, ischemic enteritis, radiation enteritis, tumors, etc

Design outcomes

Primary

Measure	Time frame	Description
the genotypes of BAFF	Baseline	multiplex polymerase chain reaction-ligase detection reaction technique

Countries

China

Outcome results